We are Unique
DEDICATED TO HUMAN PROGRESS
Our passion for science and technology is what drives our 62,770 employees in 66 countries to find solutions to some of today’s toughest challenges and create more sustainable ways to live.
We are here for people at every step, helping to create, im-prove and prolong life. We deliver personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. We empower the scientific community. Our tools, services and digital platform make research simpler, more exact, and help to deliver breakthroughs more quickly. Our solutions accelerate access to health by assuring tests are accurate and the medicine we take can be trusted. We are the company behind the companies, advancing digital living. Our science sits inside technologies that are changing the way we access, store, process, and display information. Our innovations are unlocking the power and potential of data to open new possibilities to transform life on Earth as we know it.
Thanks to the constant curiosity of our employees, we are making discoveries that can change the landscape of entire industries. For more than 350 years, we’ve been pushing the boundaries of what’s possible, and we’ll continue to do so in the years to come.
Our 62,770 colleagues around the world are driven by a common aspiration: Advancing human progress. That's what we're committed to every day – across all of our company.
Science as a force for good
Our ambition is to leverage science and technology to achieve lasting progress for mankind. For us, sustainable entrepreneurship and profitable growth go hand in hand.
Recent NewsView All News
MilliporeSigma today announced the opening of a viral clearance (VC) laboratory as part of the first building phase of its new € 29 million China Biologics Testing Center.
Merck KGaA, Darmstadt, Germany, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS).
Merck KGaA, Darmstadt, Germany, strengthens its manufacturing capabilities for single-use assemblies by investing more than € 130 million in Molsheim, France.